Last updated: February 9, 2026
What is the case about?
Celgene Corporation filed patent infringement litigation against Hikma Pharmaceuticals International Limited in the District of New Jersey. The case alleges Hikma's development and commercialization of generic versions of Celgene’s Revlimid (lenalidomide), a leading multiple myeloma treatment. Celgene asserts Hikma's infringement of multiple patents protecting Revlimid’s formulation and method of use.
What patents are involved?
Celgene’s suit centers on patents issued by the United States Patent and Trademark Office (USPTO), primarily:
- US Patent 7,906,880: Covering the crystalline formulation of lenalidomide.
- US Patent 8,184,663: Also related to formulations and uses.
- US Patent 9,720,235: Covering methods of manufacturing.
These patents are set to expire between 2025 and 2027, but Celgene seeks preliminary and permanent injunctions to prevent Hikma from launching its generic product prior to patent expiration.
How has the litigation unfolded?
The litigation involves several stages:
- Complaint Filing (October 25, 2018): Celgene files suit alleging patent infringement and seeks injunctive relief and damages.
- Hikma’s Paragraph IV Certification: Hikma certifies that its generic does not infringe and challenges the validity of the patents, triggering a 30-month stay on FDA approval if litigated.
- Patent Litigation Procedure: The case follows the typical patent litigation process, including discovery, expert disclosures, and potential claim construction hearings.
- Trial and Disposition: As of the latest update, the case remains in pretrial phases, with scheduled motions and potential settlement discussions.
What are the key legal issues?
- Patent validity: Hikma challenges whether the patents are enforceable due to obviousness, anticipation, or other validity defenses.
- Infringement: Whether Hikma’s generic formulation infringes on Celgene’s patents, explicitly or under doctrine of equivalents.
- Generic drug launch timing: Whether the court will grant an early entry by Hikma before patent expiration, possibly via a settlement or design-around.
What precedent and implications exist?
This case reflects a broader trend of patent holders in biologics and complex small-molecule drugs defending against generic entry. It underscores the value of patent thickets and the importance of patent strategies in biologics and complex chemical patents.
The outcome could influence subsequent generic challengers' strategies in litigation, settlement, and patent procurement. Courts are increasingly scrutinizing patent validity, especially in bioscience cases.
What is the potential impact on the industry?
- Market access: A ruling favoring Celgene could delay generic competition past patent expiry, impacting revenue.
- Innovation incentives: Strong patent rights support continued investment in drug development.
- Legal precedent: The case may clarify patent issues regarding complex formulations and methods, affecting other biologics and chemical drugs.
Key Takeaways
- Celgene claims Hikma infringes patents protecting Revlimid; Hikma disputes validity and non-infringement.
- The case exemplifies typical patent litigation involving paragraph IV certifications and potential 30-month stay.
- The outcome depends on patent validity findings and infringement determinations, influencing commercial timelines.
- A favorable ruling for Celgene would delay Hikma’s launch, extending market exclusivity.
- A ruling in favor of Hikma could enable earlier generic entry but might weaken patent protections for complex formulations.
FAQs
1. What is a paragraph IV certification?
A paragraph IV certification involves a generic manufacturer asserting that a patent claiming the drug is invalid or not infringed. This triggers a patent litigation stay, commonly lasting 30 months unless resolved sooner.
2. How does patent validity impact generic drug entry?
If a patent is deemed invalid or unenforceable, the generic manufacturer can launch its product earlier. Valid patents provide a legal barrier against generic entry until expiry.
3. What specific patents are challenged in this case?
Celgene holds several patents, primarily US Patent 7,906,880 (formulation), US Patent 8,184,663, and US Patent 9,720,235 (manufacturing and methods).
4. Are patent litigations like this common?
Yes, patent infringement suits involving biologics and complex small molecules are routine, especially when patent holders seek extended market exclusivity against generic entry.
5. What are the potential outcomes?
Possible outcomes include a settlement, court ruling invalidating patents, or infringement findings. Each outcome influences the timing of generic entry and company revenues.
References
[1] U.S. District Court, District of New Jersey. Celgene Corporation v. Hikma Pharmaceuticals International Limited, Case No. 2:18-cv-13477, filed October 25, 2018.
[2] USPTO Patent Database. US Patent 7,906,880; US Patent 8,184,663; US Patent 9,720,235.
[3] FDA Guidelines on Abbreviated New Drug Applications and Paragraph IV Certifications.
[4] Industry analysis reports on biologic and complex small-molecule patent strategies and litigation trends.
